Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07185269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Name: The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE — clinical trial record (NCT07185269)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Started2025-09-24

View on ClinicalTrials.gov ↗

Amendment history

2025-11-25

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-09-11→confirmed 2025-09-24

Study sitesdetails revised at 1 of 1 site

2025-09-18

Original filing

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

22 trials monitored

See all monitored trials

Lupus (SLE)

648 trials monitored

See 25 trials at risk

This study will evaluate the effect and safety of 626 in patients with SLE

Trial Details

NCT Number	NCT07185269
Lead Sponsor	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions	Systemic Lupus Erythematosus (SLE)
Enrollment	198 participants
Start Date	2025-09-24
Primary Completion	2028-08-12 (estimated)
Study Completion	2028-11-04 (estimated)
Updated on ClinicalTrials.gov	2025-11-26